Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai MedicilonSHSE:688202 -1.57%69 Days Payable is 68.78 as of Mar. 2026, which is 13% above its 10-year median of 60.88. GuruFocus rates SHSE:688202 with a GF Score™ of 69/100 and a GF Value™ of ¥45.80 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 701 Biotechnology companies, Shanghai Medicilon ranks worse than 63.91% on this metric.
The historical rank and industry rank for Shanghai Medicilon's Days Payable or its related term are showing as below:
SHSE:688202'
s Days Payable Range Over the Past 10 Years
Min: 57.34 Med: 60.88 Max: 71.62
Current: 59.04
During the past 12 years, Shanghai Medicilon's highest Days Payable was 71.62. The lowest was 57.34. And the median was 60.88.
SHSE:688202's Days Payable is ranked worse than 63.91% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs SHSE:688202: 59.04
Shanghai Medicilon's Days Payable
increased
from Mar. 2025 (60.61) to Mar. 2026 (68.78).
It may suggest that Shanghai Medicilondelayed paying its suppliers.
Shanghai Medicilon Days Payable Related Terms
Shanghai Medicilon Days Payable Historical Data
* Premium members only.
The historical data trend for Shanghai Medicilon's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688202 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Shanghai Medicilon's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Medicilon Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Medicilon's Days Payable distribution charts can be found below:
* The bar in red indicates where Shanghai Medicilon's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Shanghai Medicilon's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Medicilon (SHSE:688202) has a Days Payable of 68.78 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shanghai Medicilon and its competitors. This is 13% above median its historical median of 60.88. Over the past decade, Shanghai Medicilon's Days Payable has ranged from 57.34 to 71.62. According to the industry distribution chart, Shanghai Medicilon ranks #448 out of 701 companies in the Biotechnology industry, placing it in the top 63.9%.
Is Shanghai Medicilon's Days Payable too high?
Shanghai Medicilon's current Days Payable of 68.78 is 13% above median its 10-year median of 60.88. Over the past 10 years, this metric has ranged from a low of 57.34 to a high of 71.62. The Biotechnology industry median Days Payable is 112.84. Shanghai Medicilon's value of 68.78 is 39% below this industry median. Based on the distribution chart, Shanghai Medicilon ranks #448 out of 701 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shanghai Medicilon has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Medicilon's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Medicilon ranks #448 out of 701 companies for Days Payable. This places Shanghai Medicilon in the lower half of its industry. The industry median Days Payable is 112.84. Shanghai Medicilon's value of 68.78 is 39% below this benchmark. Historically, Shanghai Medicilon's own Days Payable has ranged from 57.34 to 71.62 over the past decade. While the company's 10-year median is 60.88 vs. the industry median of 112.84, Shanghai Medicilon has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Medicilon's current Days Payable of 68.78 is 39% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shanghai Medicilon and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Medicilon's current Days Payable is 68.78, which is 13% above median its own 10-year median of 60.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Medicilon stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Medicilon (SHSE:688202) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥45.80, compared to a current price of ¥82.82 — trading 80.8% above its estimated fair value. The current Days Payable is 68.78, which is 13% above median its 10-year median of 60.88 and 39% below the Biotechnology industry median of 112.84. Shanghai Medicilon's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Shanghai Medicilon (SHSE:688202), the current Days Payable is 68.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Medicilon (SHSE:688202) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Medicilon stock appears to be overvalued.
The current stock price of ¥82.82 is trading 80.8% above its estimated GF Value™ of ¥45.80.
GuruFocus considers Shanghai Medicilon to be Significantly Overvalued.
Key valuation signals for SHSE:688202:
Days Payable: 68.78 (13% above median its 10-year median of 60.88)
GF Value™: ¥45.80 vs. price of ¥82.82 (80.8% above fair value)
Industry Position: 39% below the Biotechnology median (#448 of 701)
No single metric tells the full story. See the SHSE:688202 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.
69GF Score
Get the complete analysis for SHSE:688202
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688202 has been successfully added to your 
